Immutep and Lonza sign agreement for cell line selection, cell banking and process development of ImmuFact(R) IMP321
13-Apr-2012 -
Immutep and Lonza announced an agreement for cell line selection, master cell banking and process development of ImmuFact(R) IMP321. Lonza will initiate the process development for Immutep’s lead product, using Immutep's newly-developed proprietary cell lines. Immutep announced Phase I/II results ...
breast cancer
cell lines
immunotherapies
+2